CN210472339U - Novel biliary tract stent - Google Patents
Novel biliary tract stent Download PDFInfo
- Publication number
- CN210472339U CN210472339U CN201920449253.5U CN201920449253U CN210472339U CN 210472339 U CN210472339 U CN 210472339U CN 201920449253 U CN201920449253 U CN 201920449253U CN 210472339 U CN210472339 U CN 210472339U
- Authority
- CN
- China
- Prior art keywords
- bile duct
- stent
- intestinal
- tail end
- biliary
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Images
Abstract
The utility model discloses a novel biliary tract stent, relating to a medical device; this support is soft and has elastic tubular structure, includes: a bile duct portion for being disposed inside the common bile duct and an intestinal tract portion for being disposed in the duodenum; the bile duct part is in a straight tube structure, and the tail end of the bile duct part is elastically coiled into a spiral ring to form an intestinal tract part; starting from the position 15cm from the tail end to the head end of the bracket, arranging bile duct side holes on the bile duct part every 1 cm; starting from the position 1cm from the tail end to the head end of the bracket, arranging intestinal side holes at intervals of 1cm on the intestinal part, wherein the intestinal side holes are positioned on the inner side of the spiral ring and face the center of the spiral ring; the stent is applied to the choledocholithiasis, and is matched with an absorbable line and a guide wire for use; can prevent the pressure of the common bile duct from increasing due to sphincter edema or scar stenosis, and prevent the occurrence of biliary fistula; can prevent the narrow sutured position of the common bile duct; can relieve gallbladder and biliary tract diseases at one time, and reduce postoperative complications such as fistula and obstructive jaundice.
Description
Technical Field
The utility model relates to a medical appliance, in particular to a novel biliary tract stent.
Background
Gallstone is a common disease and a frequently encountered disease in China, and about 3 percent of patients are accompanied with common bile duct stone; for patients with cholecystolithiasis combined with common bile duct lithiasis, the traditional operation method is to cut the abdominal wall layer by layer, cut the gallbladder, cut the common bile duct to take stones and drain by a T-shaped tube; the abdominal operation has large wound, slow recovery and long hospitalization time; with the further development of minimally invasive surgery and endoscope technology, electronic gastroscopes, electronic choledochoscopes and laparoscopes are applied more and more widely in biliary surgery; the current surgical modes aiming at the combination of cholecystolithiasis and common bile duct lithiasis comprise:
1. the method has the advantages that the ERCP can quickly relieve biliary obstruction and control infection when a patient with acute choledocholithiasis and suppurative cholangitis carries out the ERCP, the hospitalization cost is high, and complications such as pancreatitis, papillary sphincter scar stenosis and the like can occur after the operation;
2. the method comprises the steps of laparoscopic descending gallbladder resection, choledochoscope calculus removal and T-tube drainage, has the advantages that gallbladder and biliary tract diseases are removed simultaneously through one operation, and has the defects of long tube carrying time and inconvenience for life;
3. laparoscopic descending cholecystectomy, choledochoscope calculus removal and choledochoscope I-stage suture, the method has the advantages that gallbladder and biliary tract diseases are relieved at one time, T-shaped tube drainage is not needed, and the defects that nipple sphincter edema is easily caused by calculus stimulation and operation stimulation in an operation, the pressure of the choledochosis is increased, and the incidence rate of postoperative biliary fistula is obviously increased;
at present, scholars at home and abroad adopt different operation types to treat cholecystolithiasis with common bile duct lithiasis; in the field of politics and the like, a duodenoscope is combined with a laparoscope to treat cholecystolithiasis with choledocholithiasis, a T-shaped choledocholithiasis combined with choledochostomy is adopted to drain and treat cholecystolithiasis with choledochus stones when sanders occupy the sea, and a cholecystolithiasis and the choledochus combined with choledochus dissection and choledochus I-stage suture are adopted to treat cholecystolithiasis with choledochus stones when pensha and the like are used, but the incidence rate of postoperative biliary fistula is high; at present, no proposal for treating cholecystolithiasis with choledocholithiasis by a scholart by applying a biliary tract stent exists;
in view of the above situation, the utility model designs a novel biliary tract stent (shown as a real object diagram in figures 1-5) which is applied to common bile duct calculi and is matched with an absorbable line and a guide wire for use; selecting two adjacent side holes on the bile duct part according to the incision position of the common bile duct, and enabling an absorbable line to penetrate through the two selected side holes for later use; cutting a common bile duct, putting a choledochoscope in, after the choledochoscope is used for removing stones, enabling a guide wire to penetrate through a duodenal papilla under the direct vision of the choledochoscope, withdrawing the choledochoscope, enabling a biliary stent to enter duodenum through the guide wire, removing the guide wire, drawing an absorbable wire to adjust the position of the stent, putting the choledochoscope in observation again, enabling the biliary stent to smoothly pass through the duodenal papilla, enabling intestinal tract parts to be curled into a spiral ring and located in the duodenum, fixing the absorbable wire which is threaded at the upper end with a biliary tract wall suture line, and after the absorbable wire is absorbed, enabling the biliary stent to fall into the intestinal tract and be discharged out of the body after 30-60 days;
after the tubular stent is placed into the common bile duct, the common bile duct is sutured at the first stage, and one end of the stent passes through the sphincter and extends into the duodenum, so that the pressure of the common bile duct is prevented from being increased due to sphincter edema or scar stenosis, and the occurrence of biliary fistula is prevented; the other end of the bracket is placed at the junction of the left hepatic duct and the right hepatic duct, so that the narrow sutured part of the common bile duct can be prevented; the novel biliary tract stent can relieve gallbladder and biliary tract diseases at one time, and reduce postoperative complications such as biliary fistula and obstructive jaundice.
Disclosure of Invention
The utility model aims at providing a novel biliary tract stent which is applied to common bile duct calculi and is matched with an absorbable line and a guide wire for use; can prevent the pressure of the common bile duct from increasing due to sphincter edema or scar stenosis, and prevent the occurrence of biliary fistula; can prevent the narrow sutured position of the common bile duct; the novel biliary tract stent can relieve gallbladder and biliary tract diseases at one time, and reduce postoperative complications such as biliary fistula and obstructive jaundice.
The utility model adopts the technical scheme as follows: a novel biliary tract stent is characterized in that: the support is a flexible and elastic tubular structure, the head end and the tail end of the support are opened, a threading cavity for passing through a guide wire is arranged in the support, and the outer surface of the support is coated with a hydrophilic coating; this support includes: the device comprises a bile duct part and an intestinal part, wherein the bile duct part is used for being arranged inside a common bile duct, and the intestinal part is used for being arranged in duodenum and is integrally connected with the bile duct part; the bile duct part is in a straight tube structure, the tail end of the bile duct part is elastically coiled into a spiral ring to form an intestinal tract part, and the intestinal tract part is positioned on one side of the bile duct part in a naturally coiled state;
the total length of the stent is 20cm, and bile duct side holes are arranged on the bile duct part every 1cm from the tail end of the stent to the position of 15cm of the head end of the stent; starting from the position 1cm from the tail end to the head end of the bracket, arranging intestinal side holes at intervals of 1cm on the intestinal part, wherein the intestinal side holes are positioned on the inner side of the spiral ring and face the center of the spiral ring;
the stent is used in cooperation with an absorbable wire and a guide wire.
Further, the length of the bile duct part is 13cm, the length of the intestinal canal part is 7cm, namely the circumference of the spiral ring is 7cm, the specification of the stent is 8.5Fr, the thickness of the duct wall is 0.4mm, and the diameter of the threading cavity is 1.5 mm.
The number of the bile duct side holes is 5; the intestinal side holes are totally 5.
Further, the bile duct side hole is arranged on the same side or the opposite side of the intestinal tract part.
Furthermore, a graduated scale is arranged from the tail end of the bracket to the head end, and the tail end is a 0-graduation starting position.
Furthermore, the tail end of the intestinal canal part is gradually reduced in diameter and the tail end is blunt.
Further, the bracket is made of polyurethane material.
Further, the hydrophilic coating is an AQ hydrophilic coating, and polyvinylpyrrolidone is used as a coating.
The principle is as follows: the stent is used in combination with an absorbable line and a guide wire when being applied to the choledocholithiasis; selecting two adjacent side holes on the bile duct part according to the incision position of the common bile duct, and enabling an absorbable line to penetrate through the two selected side holes for later use; cutting a common bile duct, putting a choledochoscope in, after the choledochoscope is used for removing stones, enabling a guide wire to penetrate through a duodenal papilla under the direct vision of the choledochoscope, withdrawing the choledochoscope, enabling a biliary stent to enter duodenum through the guide wire, removing the guide wire, pulling an absorbable line to adjust the position of the stent, putting the choledochoscope in observation again, enabling the biliary stent to smoothly pass through the duodenal papilla, enabling intestinal tract parts to be curled into a spiral ring and located in the duodenum, enabling the absorbable line which is threaded at the upper end to be fixed with a biliary tract wall suture line, enabling the absorbable line to fall off and enter the intestinal tract after being absorbed for about 30-60 days, and discharging the absorbable line out of a body.
The beneficial effects of the utility model reside in that: the stent is applied to the choledocholithiasis, and is matched with an absorbable line and a guide wire for use; can prevent the pressure of the common bile duct from increasing due to sphincter edema or scar stenosis, and prevent the occurrence of biliary fistula; can prevent the narrow sutured position of the common bile duct; the novel biliary tract stent can relieve gallbladder and biliary tract diseases at one time, and reduce postoperative complications such as biliary fistula and obstructive jaundice.
Drawings
Fig. 1 is a schematic perspective view of the present invention.
Fig. 2 is a schematic view of a bile duct side hole of the present invention.
Fig. 3 is an enlarged schematic view of the intestinal tract of the present invention.
Fig. 4 is a schematic view of the biliary tract stent of the present invention used in cooperation with an absorbable line.
Fig. 5 is a schematic view of the biliary tract stent and the guide wire of the present invention.
Fig. 6 is a schematic diagram of the application principle of the biliary tract stent.
In the figure: head end 1, tail end 2, bile duct portion 3, intestinal portion 4, bile duct side opening 5, intestinal side opening 6, absorbable line 7, seal wire 8, scale 9.
Detailed Description
In order to make those skilled in the art better understand the technical solution of the present invention, the present invention will be further described in detail with reference to the accompanying drawings and examples, which are set forth below for illustrating the technical solution of the present invention and are not limited thereto.
A novel biliary tract stent is a soft and elastic tubular structure, the head end 1 and the tail end 2 of the stent are open, the interior of the stent is a threading cavity for passing through a guide wire 8, the outer surface of the stent is coated with a hydrophilic coating, the hydrophilic coating is an AQ hydrophilic coating, and polyvinylpyrrolidone is adopted as a coating; the coating becomes extremely smooth after contacting with water, thereby reducing the friction between the biliary tract stent and the inner wall of a human body, relieving the pain of a patient, reducing the infection chance and facilitating the operation of medical staff; meanwhile, after being sterilized, the disinfectant can be repeatedly used for many times, and is more convenient to store, transport and use;
this support includes: a bile duct portion 3 for being disposed inside the common bile duct and an intestinal portion 4 for being disposed in the duodenum, the intestinal portion 4 being integrally connected with the bile duct portion 3; the bile duct part 3 is of a straight tube structure, the tail end of the bile duct part is elastically coiled into a spiral ring to form an intestinal canal part 4, and the intestinal canal part 4 is positioned on one side of the bile duct part 3 in a naturally coiled state;
the total length of the stent is 20cm, the length of the bile duct part 3 is 13cm, the length of the intestinal tract part 4 is 7cm, namely the circumference of a spiral ring is 7cm, the specification of the stent is 8.5Fr, the thickness of the duct wall is 0.4mm, and the diameter of the threading cavity is 1.5 mm; starting from the position of 15cm from the tail end 2 to the head end 1 of the bracket, arranging a bile duct side hole 5 on the bile duct part 3 every 1 cm; starting from the position 1cm from the tail end 2 to the head end 1 of the stent, intestinal side holes 6 are arranged on the intestinal part at intervals of 1cm, and the intestinal side holes 6 are positioned on the inner side of the spiral ring and face the center of the spiral ring; the bile enters the biliary tract stent from the bile duct side hole 5, is guided by the threading cavity, flows out of the intestinal tract part 4 positioned in the duodenum, and can be smoothly guided out towards the intestinal tract side hole 6 in the center of the spiral ring, so that the bile is prevented from being contacted and blocked with the intestinal wall;
the number of the bile duct side holes 5 is 5; 5 intestinal side holes 6 are arranged; the bile duct side hole 5 is arranged on the same side with the intestinal canal part;
a graduated scale 9 is arranged from the tail end of the bracket to the head end, and the tail end 1 is a 0-graduation starting position; the graduated scale is used for accurately controlling the length of the stent entering the common bile duct according to the incision position of the incision common bile duct during an operation;
the tail end of the intestinal tract part 4 is gradually reduced in diameter, and the tail end is blunt;
the bracket is made of polyurethane material;
the stent is used in conjunction with an absorbable wire 7 and a guide wire 8.
The principle is as follows: when the stent is applied to the choledocholithiasis, the stent is matched with an absorbable line 7 and a guide wire 8 for use; according to the incision position of the common bile duct, two adjacent side holes on the bile duct part are selected, and the absorbable line 7 passes through the two selected side holes for standby; cutting a common bile duct, putting a choledochoscope in, after the choledochoscope is used for removing stones, enabling a guide wire 8 to penetrate through a duodenal papilla under the direct vision of the choledochoscope, withdrawing the choledochoscope, enabling a biliary stent to enter duodenum through the guide wire 8, removing the guide wire 8, drawing an absorbable wire 7 to adjust the position of the stent, putting the choledochoscope in observation again, enabling the biliary stent to smoothly pass through the duodenal papilla, enabling an intestinal part 4 to be coiled into a spiral ring and located in the duodenum, fixing the absorbable wire 7 which is threaded at the upper end with a suture line of the biliary wall, enabling the biliary stent to fall into the intestinal tract after the absorbable wire 7 is absorbed within about 30-60 days, and discharging the biliary stent out of a body; the spiral annular intestinal tract part 4 can fix the lower end of the biliary tract bracket in the duodenum, so that the biliary tract bracket is prevented from reversely entering a common bile duct, and the absorbable thread 7 which is threaded at the upper end of the biliary tract bracket is fixed with a biliary tract wall suture line, so that the biliary tract bracket is prevented from falling off too early and entering the intestinal tract.
Examples
1. Retrospectively analyze hospitalized patients for cholecystolithiasis with choledocholithiasis in 2015 to 2018 at 1 month and divide them into four groups by surgical means:
group A: 29 cases, first, retrograde cholangiopancreatography stone removal (ERCP + EST), then Laparoscopic Cholecystectomy (LC);
group a surgical methods: inserting duodenoscope after general anesthesia of a patient, performing retrograde cholangiopancreatography, and taking stones with a stone-taking basket after the position and the quantity of stones are determined; monitoring vital signs and blood amylase change after operation, if amylase is obviously increased, somatostatin needs to be pumped into a vein, and celioscope cholecystectomy is performed after the vital signs of a patient are stable.
Group B: 29 cases, laparoscopic descending cholecystectomy, choledochoscope lithotomy and T-tube drainage;
group B surgical methods: after the general anesthesia succeeds, firstly making a puncture hole with the length of about 1cm under the navel, inserting a laparoscope for probing, respectively making a puncture hole under the xiphoid process and the right costal margin, and excising the gall bladder after acutely dissociating the gall bladder artery and the gall bladder duct; sharp dissociation and skeletonization of common bile duct, cutting the common bile duct with a sharp blade (the common bile duct without obvious broadening may cause postoperative stenosis by electric hook cutting), stretching into a choledochoscope to explore and take stones, performing postoperative swinging T-tube drainage, suturing the common bile duct, swinging under the liver to drain, and closing the abdomen.
Group C: 17 cases, laparoscopic descending cholecystectomy + choledochoscope lithotomy + common bile duct stage i suture;
group C surgical methods: after the general anesthesia succeeds, laparoscopic cholecystectomy is performed, the common bile duct is dissociated acutely, the common bile duct is opened, explored and stone is taken, the common bile duct is continuously sutured with an 0/4 absorbable line after no stone residue is determined, and the liver is placed down to the drainage tube to close the abdomen.
Group D: 29 cases, laparoscopic descending cholecystectomy, choledochoscope lithotomy, biliary stent placement and common bile duct stage I suture;
group D surgical methods: after general anesthesia succeeds, laparoscope descending cholecystectomy is performed, the common bile duct is dissociated acutely, the common bile duct is cut by a sharp blade and is stretched into a choledochoscope to explore and take stones, after no stones are clearly left, a biliary tract stent is placed, one end of the stent penetrates through a papillary sphincter and is stretched into the duodenum, the pressure of the common bile duct can be prevented from being increased due to sphincter edema or scar stenosis, and biliary fistula and jaundice are prevented; the other end of the bracket is placed at the junction of the left hepatic duct and the right hepatic duct, so that the narrow sutured part of the common bile duct can be prevented; after the choledochoscope is inserted to confirm that the biliary stent is correctly placed, 0/4 absorbable lines are used for continuously suturing the common bile duct incision in a full layer.
2. Post-operative treatment
After ERCP operation, conventional food intake prohibition is performed, the change of blood convention, blood-urine amylase and lipase of a patient is observed, and if the blood amylase is increased, somatostatin is continuously pumped in the conventional manner; after cholecystectomy common bile duct exploration lithotomy, the change of vital signs of a patient, the color and the amount of drainage liquid, the change of biochemical indexes and abdominal signs are observed conventionally.
3. Observation index after operation
The recent observation indexes comprise the comparison of the operation time, the intraoperative hemorrhage amount, the hospitalization days, the hospitalization cost, the exhaust time, the postoperative biliary fistula and other complication incidence rates of four groups of patients; the long-term observation indexes comprise the calculus residual rate and the calculus recurrence rate of four groups of patients.
4. Statistical method
Statistical analysis is carried out by adopting SPSS19.0 software, t test is adopted for average number test, and X test is adopted for rate test2Checking; the difference in P <0.05 is statistically significant.
5. Results
5.1 general data of preoperative patients
According to inclusion criteria, 104 cases of patients who are hospitalized with choledocholithiasis and have no statistical significance for the differences of ages and sexes of the preoperative patients are totally included in 104 cases of the second affiliated hospital of Baotou medical college from 2015 1 month to 2018 month 1 month (P > 0.05);
TABLE 1 general data comparison of four groups of patients
5.2 general data of perioperative patients
The costs of hospitalization were significantly higher in ERCP + LC group than LC + LCBDE group (P <0.05) compared to ERCP + LC group, while there was no statistical difference in operative time, days of hospitalization, intraoperative bleeding volume and exsufflation time (P >0.05) (table 2);
the LC + LCBDE components are divided into B, C, D groups, and compared with the ERCP + LC group (A group), the hospitalization cost of the B group, the C group and the D group is obviously less than that of the A group (P <0.05), while the four groups of patients have no statistical difference (P >0.05) in the aspects of operation time, hospitalization days, intraoperative hemorrhage amount, exhaust time and the like, and the incidence rate of biliary fistula of the D group is obviously lower than that of the C group; other complications after surgery, such as bleeding, obstructive jaundice, and cardiovascular/cerebrovascular accidents, were not statistically significant (P >0.05) (tables 3, 4, 5, 6, 7).
TABLE 2 comparison of surgical-related data between ERCP + LC and LC + LCBDE groups
TABLE 3 comparison of four groups of surgery-related data
Hospitalization costs, comparison between groups using the LSD method: p <0.05 for a vs B; p <0.05 for a vs C; p <0.05 for a vs D;
TABLE 4B, C, D comparison of three sets of surgery-related data
TABLE 5 comparison of four groups of surgery-related data
TABLE 6C, D comparison of two sets of data relating to surgery
TABLE 7 comparison of four groups of surgery-related data
5.3 general data of postoperative patients
The observation indexes of the postoperative patients comprise the recent calculus residual rate (postoperative one month rechecking color Doppler ultrasound or MRCP) and the long-term follow-up postoperative calculus recurrence rate (postoperative three years rechecking color Doppler ultrasound or MRCP every three months); performing conventional rhinocholangiography on the third day after ERCP + EST operation if a patient has no pancreatitis, and removing the rhinocholangiography after no calculus residue is clear; patients in group B have confirmed whether there is calculus after 3-5 days of operation by T-tube radiography, and if there is no calculus residue, the patient is returned home with the tube, and the T-tube is removed 6-8 weeks after the operation; patients in groups C and D have normal postoperative recheck of liver function, color Doppler ultrasound or MRCP, and are discharged after recovery without calculus residues; the biliary tract stent of the patient in group D is discharged from anus with excrement 5-7 days after the operation; one postoperative calculus remained in all four patients except group A, and no calculus remained in all other three groups (P >0.05), with no statistical difference (Table 8).
All patients had outpatient visits and telephone follow-up visits of 3 months, 6 months and 1 year after the operation; the postoperative follow-up time is 1-3 years, and the average is 18 months; after surgery, 3 cases of recurrence of common bile duct stones were found in group a, 1 case of recurrence of common bile duct stones in group B and group D, and 2 cases of recurrence of common bile duct stones in group C, with no statistical difference (P >0.05) (table 9).
TABLE 8 comparison of four sets of postoperative related data
TABLE 9 comparison of four sets of postoperative relevant data
Comparing the indexes of the four groups of patients, such as operation time, intraoperative hemorrhage amount, hospitalization days, hospitalization cost, exhaust time, postoperative biliary fistula, calculus residual rate, calculus recurrence rate and the like; results the hospitalization costs of group D were significantly less than those of group a (P <0.05), whereas patients of group D were statistically less different (P >0.05) than those of group B and group C in terms of operative time, days of hospitalization, intraoperative bleeding volume, hospitalization costs, etc., and the incidence of biliary fistula was significantly less than that of group C (P < 0.05).
Research proves that the biliary tract stent is placed after cholecystectomy choledochostomy, the operation time and the hospitalization days of a patient are not prolonged, the hospitalization cost of the patient is not increased, a plurality of inconveniences caused by long-time T-shaped tube wearing are avoided, and postoperative complications such as biliary fistula and obstructive jaundice are reduced;
for patients without sphincter edema, stenosis and suppurative cholangitis, the biliary tract stent is directly placed into the common bile duct and can be discharged into the intestinal tract after 3-5 days, and for patients with obvious inflammation or obvious papillary sphincter scar stenosis, the biliary tract stent is fixed on the wall of the biliary tract by absorbable suture, so that the discharge time of the biliary tract stent can be delayed; the time for the absorbable suture to be completely absorbed and dissolved is about 30 to 60 days at present, namely the biliary tract stent can be discharged into the intestinal tract after 30 to 60 days.
Although the present invention has been described in detail with reference to the foregoing embodiments, it will be apparent to those skilled in the art that various changes and modifications can be made in the embodiments described in the foregoing embodiments, or equivalent changes and modifications can be made in some of the technical features of the embodiments.
Claims (8)
1. A novel biliary tract stent is characterized in that: the support is a flexible and elastic tubular structure, the head end and the tail end of the support are opened, a threading cavity for passing through a guide wire is arranged in the support, and the outer surface of the support is coated with a hydrophilic coating; this support includes: the device comprises a bile duct part and an intestinal part, wherein the bile duct part is used for being arranged inside a common bile duct, and the intestinal part is used for being arranged in duodenum and is integrally connected with the bile duct part; the bile duct part is in a straight tube structure, the tail end of the bile duct part is elastically coiled into a spiral ring to form an intestinal tract part, and the intestinal tract part is positioned on one side of the bile duct part in a naturally coiled state;
the total length of the stent is 20cm, and bile duct side holes are arranged on the bile duct part every 1cm from the tail end of the stent to the position of 15cm of the head end of the stent; starting from the position 1cm from the tail end to the head end of the bracket, arranging intestinal side holes at intervals of 1cm on the intestinal part, wherein the intestinal side holes are positioned on the inner side of the spiral ring and face the center of the spiral ring;
the stent is used in cooperation with an absorbable wire and a guide wire.
2. The novel biliary stent of claim 1, wherein: the length of the bile duct part is 13cm, the length of the intestinal canal part is 7cm, namely the circumference of the spiral ring is 7cm, the specification of the stent is 8.5Fr, the thickness of the tube wall is 0.4mm, and the diameter of the threading cavity is 1.5 mm.
3. The novel biliary stent of claim 1, wherein: the number of the bile duct side holes is 5; the intestinal side holes are totally 5.
4. The novel biliary stent of claim 1, wherein: the bile duct side hole is arranged on the same side or the opposite side of the intestinal tract part.
5. The novel biliary stent of claim 1, wherein: a graduated scale is arranged from the tail end of the bracket to the head end, and the tail end is a 0-graduation starting position.
6. The novel biliary stent of claim 1, wherein: the tail end diameter size of intestinal canal portion reduces gradually, and the tail end is round blunt type.
7. The novel biliary stent of claim 1, wherein: the bracket is made of polyurethane material.
8. The novel biliary stent of claim 1, wherein: the hydrophilic coating is an AQ hydrophilic coating, and polyvinylpyrrolidone is used as a coating.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201920449253.5U CN210472339U (en) | 2019-04-04 | 2019-04-04 | Novel biliary tract stent |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201920449253.5U CN210472339U (en) | 2019-04-04 | 2019-04-04 | Novel biliary tract stent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN210472339U true CN210472339U (en) | 2020-05-08 |
Family
ID=70486579
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201920449253.5U Expired - Fee Related CN210472339U (en) | 2019-04-04 | 2019-04-04 | Novel biliary tract stent |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN210472339U (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112999497A (en) * | 2021-02-08 | 2021-06-22 | 东莞市南城医院 | Self-discharging type common bile duct built-in drainage dilatation catheter |
-
2019
- 2019-04-04 CN CN201920449253.5U patent/CN210472339U/en not_active Expired - Fee Related
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112999497A (en) * | 2021-02-08 | 2021-06-22 | 东莞市南城医院 | Self-discharging type common bile duct built-in drainage dilatation catheter |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Huffman et al. | Treatment of distal ureteral calculi using rigid ureteroscope | |
| US8585719B2 (en) | Instrument for anorectal surgery | |
| CN210472339U (en) | Novel biliary tract stent | |
| CN201098224Y (en) | Inner support of biliary tract capable of falling off | |
| US20150217100A1 (en) | Urethral stricture treatment method | |
| RU2334472C1 (en) | Method of papilosphincterotomy | |
| RU2661093C1 (en) | Method for placing a ureteral stent catheter in upper urinary tract laparoscopic surgeries | |
| Jia et al. | A comparative study on the efficacy of retroperitoneoscopic pyeloplasty and open surgery for ureteropelvic junction obstruction in children | |
| RU57123U1 (en) | Cylinder catheter with tags for intraoperative endobiliary dilatation | |
| CN203802607U (en) | Preternatural anus | |
| CN103816602A (en) | Biliary tract inner support drainage tube | |
| Grange et al. | Eroded tape: a case of an early vesicoscopy rather than laser melting | |
| RU2763979C1 (en) | Method for percutaneous cystolithotripsy in patients with bladder outlet obstruction | |
| RU2654412C1 (en) | Method for remove concrements from bile ducts after previous cholecystectomy | |
| RU2757530C2 (en) | Method for percutaneous antegrade treatment of recurrent short strictures up to 10 mm of ureteropelvic junction in children with hydronephrosis | |
| RU2790762C1 (en) | Urethral speculum female (options) | |
| CN103908355B (en) | Artificial anus | |
| RU2253382C1 (en) | Method for antegrade bipolar papillosphincterotomy | |
| RU2814386C1 (en) | Method for extracting colon preparation through natural openings of human body | |
| RU2776963C1 (en) | Method for percutaneous cystolithotripsy for large stones | |
| RU2751281C2 (en) | Method for endoscopic treatment of strictures of the main pancreatic duct | |
| RU223673U1 (en) | URETHRAL OPTICAL CATHETER FOR SAFE BLADDER DRAINAGE | |
| RU2753473C1 (en) | Device for implementing a method for treating chronic paraproctitis complicated by the formation of transsphincter or extrasphincter fistulas of the rectum | |
| RU2802130C2 (en) | Method of performing extraurethral retropubic adenomectomy | |
| RU2556574C1 (en) | Method for minimally invasive combination treatment of choledocholithiasis accompanying atypical position of major duodenal papilla |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20200508 |